Journal Information
Visits
159
Scientific letter
Full text access
Available online 10 July 2024
Intestinal histoplasmosis in an immunocompetent patient: A case report
Histoplasmosis intestinal en un paciente inmunocompetente: reporte de un caso
Visits
159
C.E. Alcántara-Figueroaa,b,
Corresponding author
christian378@hotmail.com

Corresponding author. Calle Las Camelias 791-795, Dpto 502, Urb. Las Palmeras del Golf, distrito Víctor Larco Herrera, Trujillo, La Libertad, Peru. Tel.: +51969672075.
, E.F. Coronado-Riveraa,c
a Escuela de Medicina, Universidad Privada Antenor Orrego, Trujillo, La Libertad, Peru
b Servicio de Gastroenterología, Hospital Belén, Trujillo, La Libertad, Peru
c Servicio de Anestesiología y Centro Quirúrgico, Hospital Víctor Lazarte Echegaray, Trujillo, La Libertad, Peru
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text

Histoplasmosis is an endemic mycosis caused by the Histoplasma capsulatum fungus. This fungus is acquired through the inhalation of microconidia and more than 90% of cases are asymptomatic.1 Symptomatic intestinal involvement is extremely rare and clinical presentation depends on patient age and immunosuppression status, as well as on the size of the inoculum.2

A 45-year-old man from Tarapoto, Peru, came to the hospital presenting with diffuse, colicky abdominal pain, bloody diarrhea, diaphoresis, and fever of 38 °C for a period of three weeks. He went to the emergency service for having presented with hematochezia. Laboratory analyses reported the following: leukocytes: 10,000/mm3, bands: 0%, segmented cells: 88.9%, hemoglobin: 7.8 g/dl, platelets: 346,000/mm3, ELISA HIV: nonreactive, HTLV I and II: negative. Colonoscopy: multiple ulcers in the ascending colon, transverse colon, descending colon, sigmoid colon, and rectum, with congestive edges and whitish fibrin in the wound bed (Fig. 1a). The pathologic anatomy study of the colonic biopsies showed chronic inflammation and multiple macrophages, with microorganisms in their interior, consistent with histoplasma (Fig. 1b). Gomori staining was positive for mycosis (Fig. 1c). Intravenous liposomal amphotericin B, 3 mg/kg/day, was administered for 2 weeks. The patient had clinical improvement and was discharged. As an outpatient, he continued treatment with itraconazole, 200 mg every 12 hours, for one year. At the one-year follow-up, the patient is asymptomatic.

Figure 1.

a) the presence of ulcers in the sigmoid colon, b) the pathologic anatomy study with hematoxylin-eosin staining revealed multiple purple, sphere-shaped microorganisms, surrounded by a whitish halo, consistent with histoplasmosis, and c) Gomori staining showed the presence of multiple microorganisms consistent with mycosis.

(0.18MB).

In Latin America, histoplasmosis is highly endemic, with a prevalence of 32%. This mycosis can manifest from the mouth to the anus; the most frequently affected sites are the ileum and colon.3 Intestinal manifestations occur in 2-3% of cases and the most frequently reported clinical symptoms are abdominal pain, diarrhea, and fever.4 Endoscopically, histoplasmosis involving the colon can present as an ulcer or pseudotumor, and there can be complications, such as gastrointestinal bleeding, intestinal obstruction, or intestinal perforation.5 Diagnosis consists of the presence of microorganisms in the histology study, which in hematoxylin-eosin staining are characteristically round, purple, and surrounded by a whitish halo. Other infections, such as tuberculosis, inflammatory bowel disease, or neoplastic processes, such as lymphoma, should be considered in the differential diagnosis.6 In disseminated forms, the treatment of choice is 3 mg/kg/day of liposomal amphotericin B for 1-2 weeks, followed by itraconazole 200 mg every 8 hours for 3 days, and then itraconazole 200 mg every 12 hours for 12 months.7,8

In conclusion, intestinal histoplasmosis can appear in immunocompetent patients from endemic zones, with the clinical symptoms of abdominal pain, diarrhea, and fever.

Ethical considerations

The authors declare that no experiments were conducted on humans for this research. We utilized the protocols of our work center for obtaining patient databases, preserving patient anonymity (thus informed consent was not requested). This study meets the current bioethical research regulations.

Financial disclosure

No financial support was received in relation to this article.

Conflict of interest

The authors declare that there is no conflict of interest.

References
[1]
B.E. Ekeng, A.E. Itam-Eyo, I.I. Osaigbovo, et al.
Gastrointestinal histoplasmosis: a descriptive review, 2001-2021.
Life (Basel)., 13 (2023), pp. 689
[2]
J.P. Donelly, S.C. Chen, C.A. Kauffman, et al.
Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.
Clin Infect Dis., 71 (2020), pp. 1367-1376
[3]
A.B. Araúz, P. Papineni.
Histoplasmosis.
Infect Dis Clin North Am., 35 (2021), pp. 471-491
[4]
F. Sangiorgi, R. Torelli, F. Castri, et al.
Colonic histoplasmosis.
J Travel Med., 30 (2023),
[5]
Y. Hamada, K. Tanaka, N. Horiki, et al.
Colonic histoplasmosis resembling early colon cancer.
Gastrointest Endosc., 91 (2020), pp. 951-952
[6]
L.L. Zhu, J. Wang, Z.J. Wang, et al.
Intestinal histoplasmosis in immunocompetent adults.
World J Gastroenterol., 22 (2016), pp. 4027-4033
[7]
M.M. Azar, J.L. Loyd, R.F. Relich, et al.
Current concepts in the epidemiology, diagnosis, and management of histoplasmosis syndromes.
Semin Respir Crit Care Med., 41 (2020), pp. 13-30
[8]
G.R. Thompson 3rd, T. Le, A. Chindamporn, et al.
Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology.
Lancet Infect Dis., 21 (2021), pp. e364-e374
Copyright © 2024. Asociación Mexicana de Gastroenterología
Idiomas
Revista de Gastroenterología de México
Article options
Tools
es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.